Imviva Bio

Imviva is a clinical-stage biotechnology company developing personalized, autologous cell-based immunotherapies for the treatment of solid tumors. The company's lead candidate, IGV-001, is currently in Phase 2b clinical trials for newly diagnosed glioblastoma multiforme (GBM). Imviva's unique approach involves treating a patient's own tumor cells with an antisense oligonucleotide targeting the IGF-1 receptor, then re-implanting them via a biodiffusion chamber to trigger a systemic immune response. By leveraging the full spectrum of a patient's tumor antigens, the company aims to overcome the limitations of single-antigen therapies in complex cancers. The technology was originally developed at Thomas Jefferson University and represents a novel method of in vivo immune activation. Imviva is headquartered in Philadelphia and is backed by prominent life science investors.